Raj R. Makkar

Oct 29, 2024 | jamanetwork.com | Raj R. Makkar |Aakriti Gupta |Samuel Horr |Thomas E. Waggoner

Key PointsQuestion  Are there regional differences in the association between use of cerebral embolic protection (CEP) and stroke outcomes in patients undergoing transcatheter aortic valve replacement (TAVR)? Findings  In the PROTECTED TAVR randomized clinical trial including 3000 patients, no significant difference was found in stroke rates with CEP nor in interaction by geographic region.

Oct 6, 2024 | jacc.org | Suzanne Arnold |Rebecca T. Hahn |Vinod Thourani |Raj R. Makkar

Introduction Severe tricuspid regurgitation (TR) can result in a substantial burden of symptoms, such as dyspnea, fatigue, and edema, which can negatively impact patients’ physical and social function and their quality of life.1-4 Although it was expected that treatment of severe TR would lead to reductions in both mortality and heart failure hospitalization, to date, the only proven benefit of transcatheter tricuspid valve intervention is improved health status.5-7 In both the TRILUMINATE...

Jun 21, 2024 | citoday.com | Aakriti Gupta |Moody Makar |Raj R. Makkar

Severe tricuspid regurgitation (TR) is a prevalent valvular heart disease, particularly among older populations and those with heart failure, resulting in high mortality with a 5-year survival rate below 30% and increased hospitalizations related to heart failure and atrial fibrillation.1 Although the majority of TR cases are functional, caused by structural changes in the heart such as annular dilatation and leaflet tethering, surgical interventions remain underutilized due to high...

Oct 25, 2023 | icrjournal.com | Michael Reardon |Joost Daemen |Raj R. Makkar

TCT 23 - In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from the EVOLUT Low-Risk Trial (NCT03635424), sponsored by Medtronic. The EVOLUT Low-risk trial is a multicenter, prospective, single-arm study which aimed to assess the procedural safety and efficacy of the Medtronic TAVR system in 150 patients with bicuspid aortic anatomy and severe aortic stenosis, who are at low-risk for SAVR.

Oct 9, 2023 | icrjournal.com | Raj R. Makkar |Joost Daemen

Please note that the text below has not been copyedited. Dr Raj Makkar: I'm Raj Makkar, I'm an interventional cardiologist at Cedar Sinai Medical Centre in Los Angeles. What is the importance of this study? So, as transcatheter aortic valve replacement is being now used in younger patients who are likely to outlive the durability of the bioprosthetic valve, it is important for us to gather data on the safety of a repeat transcatheter aortic valve replacement.